8-K
filed June 12, 2026, 4:01 PM ET
ticker DARE
CIK 0001401914
other material
confidence high
sentiment neutral
materiality 0.50
Daré Bioscience stockholders approve 1.5M share increase in 2022 plan and ratify auditor
Dare Bioscience, Inc.
- Stockholders approved amendment to 2022 Stock Incentive Plan adding 1,500,000 shares; total reserve becomes 2,883,333 shares.
- Elected directors Gregory W. Matz (3,752,211 votes for) and Sabrina Martucci Johnson (3,848,085 votes for).
- Ratified Haskell & White LLP as independent auditor for FY2026 (7,754,883 votes for).
- Approved potential future issuances under Lincoln Park Capital equity line (3,771,709 votes for).
- Say-on-pay approved (3,625,596 votes for); board set advisory vote frequency at every year.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dare Bioscience, Inc. shareholders approved Adjournment of meeting to solicit additional proxies for Proposal 5 if necessary at the 2026-06-11 meeting.
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 7 : Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 5 if there were not sufficient votes to approve Proposal 5 by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dare Bioscience, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2026-06-11 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 3 : Our stockholders approved, on an advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dare Bioscience, Inc. shareholders approved Approval of potential future issuance of shares under equity line with Lincoln Park Capital Fund, LLC (Nasdaq rule) at the 2026-06-11 meeting.
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 5 : Our stockholders approved, in accordance with Nasdaq rules, the potential future issuance of shares of our common stock under our existing equity line with Lincoln Park Capital Fund, LLC by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dare Bioscience, Inc. shareholders approved Adjournment of meeting to solicit additional proxies for Proposal 6 if necessary at the 2026-06-11 meeting.
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 8 : Our stockholders approved the adjournment of the Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 if there were not sufficient votes to approve Proposal 6 by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dare Bioscience, Inc. shareholders approved Approval of amendment to 2022 Stock Incentive Plan to increase shares available by 1,500,000 at the 2026-06-11 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 6 : Our stockholders approved the 2022 Plan Amendment by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dare Bioscience, Inc. shareholders approved Advisory vote on preferred frequency of holding advisory vote on executive compensation at the 2026-06-11 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 4 : Our stockholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation of our named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dare Bioscience, Inc. shareholders approved Election of Class III directors at the 2026-06-11 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 1 : Each of the director nominees identified in the table below was elected as a Class III director to hold office until our 2029 annual meeting of stockholders, and until their respective successor is duly elected and qualified, by the votes set forth below.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dare Bioscience, Inc. shareholders approved Ratification of appointment of Haskell & White LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal 2 : Our stockholders ratified the appointment of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 by the votes set forth below.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.